Kyxata
Payments companies reported to CMS as associated with Kyxata. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Kyxata, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Kyxata
These are the largest totals companies reported as associated with Kyxata. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Edward Licitra | East Brunswick, NJ | Medical Oncology | $366.62 |
| Samir Desai | Plainfield, IL | Hematology & Oncology | $269.52 |
| Salman Waheed | Joliet, IL | Hematology & Oncology | $269.52 |
| Shalin Shah | Plainfield, IL | Internal Medicine | $269.52 |
| Ranjana Chauhan | Hinsdale, IL | Ophthalmology | $269.52 |
| Aditi Sanatinia | Las Vegas, NV | Obstetrics & Gynecology | $185.32 |
| Hamidreza Sanatinia | Las Vegas, NV | Hematology & Oncology | $185.32 |
| Kavita Kalra | Baltimore, MD | Hematology & Oncology | $167.30 |
| Josy Mathew | Concord, NH | Hematology & Oncology | $167.30 |
| Carl Minniti | Mickleton, NJ | Hematology & Oncology | $167.30 |
Prescribed Kyxata?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.